Stock VNDA VANDA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-20 pm EDT 		5-day change 1st Jan Change
5.27 USD -3.83% Intraday chart for Vanda Pharmaceuticals Inc. +4.36% +24.88%
May. 15 Vanda Pharmaceuticals Says Second Phase 3 Study of Tradipitant in Motion Sickness Yields 'Positive' Results MT
May. 15 Vanda Pharmaceuticals Inc. Reports Positive Results from A Second Phase III Study of Tradipitant in Motion Sickness CI

Evolution of the average Target Price on Vanda Pharmaceuticals Inc.

Price target over the last 5 years

History of analyst recommendation changes

30789d51e83458e.7oCLSe0dCw9YfzzDQjjgeCMwR7twcxl6EBCjKtzS9Dc.o-raPdxEYG1hNWOocVqTQGl-AtkvSikOdmbAcqS-hACH-e9xjClUQj5PVw~2ffe898de3074d8bfe2a5ad277151dbd

Analyst Recommendations on Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Adopts Stockholder Rights Plan; Shares Rise MT
Vanda Pharmaceuticals' Board Rejects all Unsolicited Takeover Proposals From Future Pak MT
Oil ticks up as markets weigh U.S. debt deal, rate hike possibility RE
Jefferies Downgrades Vanda Pharmaceuticals to Hold From Buy, Adjusts Price Target to $12 From $24 MT
Wall Street Sees Lower Open as Jobs Report Stirs Interest Rate Fears MT
VANDA PHARMACEUTICALS : BofA Securities Starts Vanda Pharmaceuticals at Buy With $22 Price Target MT
VANDA PHARMACEUTICALS : Citigroup Downgrades Vanda Pharmaceuticals to Neutral From Buy; Price Target is $14 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
5.27 USD
Average target price
5.21 USD
Spread / Average Target
-1.14%
High Price Target
5.21 USD
Spread / Highest target
-1.14%
Low Price Target
5.21 USD
Spread / Lowest Target
-1.14%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Vanda Pharmaceuticals Inc.

Jefferies & Co.
BofA Securities
Citigroup

Ratings for Vanda Pharmaceuticals Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. VNDA Stock
  4. Consensus Vanda Pharmaceuticals Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW